These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25319658)

  • 61. The challenges of targeting chronic myeloid leukemia stem cells.
    Jiang X; Smith C; Eaves A; Eaves C
    Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 2():S71-80. PubMed ID: 17382016
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?
    Richter J; Söderlund S; Lübking A; Dreimane A; Lotfi K; Markevärn B; Själander A; Saussele S; Olsson-Strömberg U; Stenke L
    J Clin Oncol; 2014 Sep; 32(25):2821-3. PubMed ID: 25071107
    [No Abstract]   [Full Text] [Related]  

  • 63. Novel therapies for chronic myelogenous leukemia.
    Jahagirdar BN; Miller JS; Shet A; Verfaillie CM
    Exp Hematol; 2001 May; 29(5):543-56. PubMed ID: 11376866
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia.
    Vysochinskaya V; Dovbysh O; Gorshkov A; Brodskaia A; Dubina M; Vasin A; Zabrodskaya Y
    Biomolecules; 2024 May; 14(6):. PubMed ID: 38927048
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The role of phosphorylation of MLF2 at serine 24 in BCR-ABL leukemogenesis.
    Yang J; Cao D; Zhang Y; Ou R; Yin Z; Liu Y; Huang G; Gu C; Chen S; Fei J
    Cancer Gene Ther; 2020 Feb; 27(1-2):98-107. PubMed ID: 31831854
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.
    Proschmann R; Baldow C; Rothe T; Suttorp M; Thiede C; Tauer JT; Müller MC; Hochhaus A; Roeder I; Glauche I
    Haematologica; 2017 Feb; 102(2):e39-e42. PubMed ID: 27856510
    [No Abstract]   [Full Text] [Related]  

  • 67. [Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group].
    Hochhaus A; Berger U; Reiter A; Engelich G; Lahaye T; Kreil S; Merx K; Müller MC; Hehlmann R
    Internist (Berl); 2002 Oct; 43(10):1228, 1231-8, 1241-4. PubMed ID: 12524904
    [No Abstract]   [Full Text] [Related]  

  • 68. Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment.
    Mendonça LS; Moreira JN; de Lima MC; Simões S
    Biotechnol Bioeng; 2010 Dec; 107(5):884-93. PubMed ID: 20632368
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence.
    Gavrilov K; Seo YE; Tietjen GT; Cui J; Cheng CJ; Saltzman WM
    Proc Natl Acad Sci U S A; 2015 Dec; 112(48):E6597-605. PubMed ID: 26627251
    [TBL] [Abstract][Full Text] [Related]  

  • 70. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
    Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
    J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.
    Hato T; Yamanouchi J; Tamura T; Hojo N; Niiya Y; Kohno M; Bando S; Yakushijin Y; Takada K; Sakai I; Yasukawa M; Fujita S
    Int J Hematol; 2004 Jul; 80(1):62-6. PubMed ID: 15293570
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Reply to J. Richter et al.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Sep; 32(25):2823-5. PubMed ID: 25071119
    [No Abstract]   [Full Text] [Related]  

  • 73. [Recent progress in diagnosis of and therapy for patients with leukemia].
    Ueda T
    Nihon Naika Gakkai Zasshi; 2004 Mar; 93(3):574-9. PubMed ID: 15052823
    [No Abstract]   [Full Text] [Related]  

  • 74. Differential gene expression changes and their implication on the disease progression in patients with Chronic Myeloid Leukemia.
    Chandran RK; Geetha N; Sakthivel KM; Kumar RS; Krishna KMNJ; Sreedharan H
    Blood Cells Mol Dis; 2019 Jul; 77():51-60. PubMed ID: 30959263
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effective Downregulation of BCR-ABL Tumorigenicity by RNA Targeted CRISPR-
    Singh A; Bhatia P
    Curr Gene Ther; 2021; 21(3):270-277. PubMed ID: 33596804
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence.
    Takeishi S; Matsumoto A; Onoyama I; Naka K; Hirao A; Nakayama KI
    Cancer Cell; 2013 Mar; 23(3):347-61. PubMed ID: 23518349
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing.
    Hong CA; Cho SK; Edson JA; Kim J; Ingato D; Pham B; Chuang A; Fruman DA; Kwon YJ
    ACS Nano; 2016 Sep; 10(9):8705-14. PubMed ID: 27472284
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Longitudinal Study to Assess the Clinical Significance of MSI2 Expression in Chronic Myeloid Leukemia Patients.
    Kaeda J; Ringel F; Oberender C; Gresse M; Amini L; Schwarz M; Dörken B; le Coutre P
    Acta Haematol; 2016; 136(1):62-4. PubMed ID: 27160312
    [No Abstract]   [Full Text] [Related]  

  • 79. Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro.
    Vysochinskaya V; Zabrodskaya Y; Dovbysh O; Emelyanov A; Klimenko V; Knyazev N; Terterov I; Egorova M; Bogdanov A; Maslov M; Vasin A; Dubina M
    Biochimie; 2024 Jun; 221():1-12. PubMed ID: 38215931
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lipocalin-2 is associated with modulation of disease phenotype in a patient with concurrent JAK2-V617F and BCR-ABL mutation.
    Nadarajan VS; Ang CH; Bee PC
    Eur J Haematol; 2012 Feb; 88(2):175-8. PubMed ID: 21950422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.